Targeted therapy for HER2 positive breast cancer

Journal of Hematology & Oncology

Janice Lu¹  Ying Mu¹  Shilpan Shah²  Jason A Incorvati² 

[1] Breast Center, Shijitan Hospital, Capital Medical University, Beijing, China;Department of Medicine, State University of New York at Stony Brook Medical Center, Stony Brook, NY, USA

关键词: San Antonio 2012;    ASCO 2012;    Breast cancer;    HER2 positive;   

Others  :  806106
DOI  :  10.1186/1756-8722-6-38

 received in 2013-03-27, accepted in 2013-05-02,  发布年份 2013

【 摘 要 】

Introduction

Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45–55 years old (CDC.gov 2012). Although there continue to be enormously large numbers of disease incidence, deaths have been declining due to the disease with two hallmark time frames. The first occurred during the mid to late 1980’s when hormonal therapy was introduced as a treatment for ER/PR positive breast cancer. The second occurred in the late 1990’s when trastuzumab was introduced in treating HER2 positive breast cancer. These remarkable accomplishments in developing novel targeted therapies for breast cancer, along with a better understanding of the disease biology have improved disease outcome over the past 20 years.

This article reviews the data presented at 2012 American Society of Clinical Oncology and 2012 San Antonio Breast Cancer Symposium regarding progress made in the field of HER2 positive breast cancer and examines the future of HER2 targeted therapy.

【 授权许可】

   
2013 Incorvati et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]CDC.gov: Breast Cancer Statistics. 2012. http://cdc.gov/cancer/breast/statistics webcite
• [2]Bailey TA, Luan H, Clubb RJ, et al.: Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog 2011, 10:28.
• [3]Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655.
• [4]Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L: Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9:16-32.
• [5]Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist 1998, 3:237-252.
• [6]Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erb-B2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clinical Oncology 1998, 16:462-469.
• [7]Albain KS, Allred DC, Clark GM: Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994, 16:35-42.
• [8]Russell KS, Hung MC: Transcriptional repression of the neu proto-oncogene by estrogen stimulated estrogen receptor. Cancer Res 1992, 52:6624-6629.
• [9]Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
• [10]Goldhirsch A, Piccart-Gebhart MJ, Procter M, et al.: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res 2012, 72(24 Suppl):103s-104s. San Antonio Breast Conference Abstracts 2012
• [11]Pivot X, Romieu G, Bonnefoi H, et al.: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Cancer Res 2012, 72(24 Suppl):104s. San Antonio Breast Conference Abstracts 2012
• [12]Earl HM, Cameron DA, Miles D, et al.: PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer. Cancer Res 2012, 72(24 Suppl):557s-558s. San Antonio Breast Conference Abstracts 2012
• [13]Romond EH, Suman VJ, Jeong J-H, et al.: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Cancer Res 2012, 72(24 Suppl):105s. San Antonio Breast Conference Abstracts 2012
• [14]Montemurro F, Valabrega G, Aglietta M: Lapatinib: A dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007, 7:257-268.
• [15]Geyer CE, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
• [16]Robidoux A, Tang G, Rastogi P, et al.: Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. ASCO Meeting Abstracts 2012., 30LBA506
• [17]Takano T, Kimura H, Nishio K, et al.: WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes. ASCO Meeting Abstracts 2012., 30TPS659
• [18]Aktas B, Kümmel S, Krocker J, et al.: Phase I/II Trial of primary chemotherapy with non-pegylated liposomal doxorubicin, paclitaxel and lapatinib in patients with HER2-positive, early stage breast cancer. Cancer Res 2012, 72(24 Suppl):201s-202s. San Antonio Breast Conference Abstracts 2012
• [19]Kodack DP, Chung E, Yamashita H, et al.: Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Cancer Res 2012, 72(24 Suppl):341s-342s. San Antonio Breast Conference Abstracts 2012
• [20]Gelmon K, Boyle F, Kaufman B, et al.: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clinical Oncology 2012, 30:LBA671.
• [21]Estevez LG, Suarez A, Calvo I, et al.: Molecular effects of lapatinib in HER2 positive ductal carcinoma in situ (DCIS). Cancer Res 2012, 72(24 Suppl):471s. San Antonio Breast Conference Abstracts 2012
• [22]Blackwell KL, Burstein HJ, Storniolo AM, et al.: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012, 30(21):2585-2592.
• [23]Johnston S, Wroblewski S, Huang Y, et al.: ALTERNATIVE: safety and efficacy of lapatinib (L), trastuzumab (T), or both in combination with an aromatase inhibitor (AI) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer. Cancer Res 2012, 72(24 Suppl):558s. San Antonio Breast Conference Abstracts 2012
• [24]Crown JP, Moulton B, O’Donovan N, et al.: A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer. Cancer Res 2012, 72(24 Suppl):559s. San Antonio Breast Conference Abstracts 2012
• [25]Lin N, Danso MA, David AK, et al.: Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515). Cancer Res 2012, 72(24 Suppl):559s. San Antonio Breast Conference Abstracts 2012
• [26]Gradishar WJ: HER2 therapy-an abundance of riches. N Engl J Med 2012, 366(2):176-178.
• [27]Gianni L, Pienkowski T, Im YH, et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomized multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
• [28]Baselga J, Cortes J, Kim S-B, et al.: Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 2012, 366:109-119.
• [29]Swain S, Kim S-B, Cortes J, et al.: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival from a randomized, double-blind, placebo-controlled, phase III study. Lancet Oncol 2013. Published Online: 18 April 2013
• [30]A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. 2012. http://www.ibcsg.org/Public/Health_Professionals/Open_Trials/IBCSG_39-11/Pages/IBCSG39-11BIG4-11_APHINITY.aspx webcite
• [31]Perez EA, Lopez-Vega JM, Del Mastro L, et al.: A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET). ASCO Meeting Abstracts 2012., 30TPS653
• [32]Rimawi MF, Poole CJ, Ferrero J-M, et al.: Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN). ASCO Meeting Abstracts 2012., 30TPS654
• [33]Baselga J, Cortés J, Im S-A, et al.: Biomarker analyses in CLEOPATRA: A phase III, placebo, controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 2012, 72(24 Suppl):103s. San Antonio Breast Conference Abstracts 2012
• [34]Miles D, Baselga J, Amadori D, et al.: Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. Cancer Res 2012, 72(24 Suppl):464s-465s. San Antonio Breast Conference Abstracts 2012
• [35]Bachelot T, Ciruelos E, Peretz-Yablonski T, et al.: A single-arm phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE). Cancer Res 2012, 72(24 Suppl):557s. San Antonio Breast Conference Abstracts 2012
• [36]Gavilá J, Llombart A, Guerrero A, et al.: Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER 2-positive breast cancer. 2012, 560s-561s. [San Antonio Breast Conference Abstracts]
• [37]Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA: Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol 2013, 31:1157-63.
• [38]Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J, Pegram M, Oh D, Dieras V, Guardino E, Fang L, Lu M, Olsen S, Blackwell K: Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012, 367:1783-1791.
• [39]ClinicalTrials.gov [Internet]: Bethesda (MD): National Library of Medicine (US). 2010 April 28. Identifier NCT01120184, A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). 2010. http://clinicaltrials.gov/show/NCT01120184 webcite
• [40]Wang B, Jin J, Wada R, et al.: Pharmacokinetics and exposure-efficacy relationship of trastuzumab emtansine in EMILIA, a phase 3 study of trastuzumab emtansine vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer. Cancer Res 2012, 72(24 Suppl):469s-470s.
• [41]Cristofanilli M, Johnston SRD, Manikhas A, et al.: A randomized phase II study (VEG108838) of lapatinib plus pazopanib (L + P) versus lapatinib (L) in patients with ErbB2+ inflammatory breast cancer (IBC). ASCO Meeting Abstracts 2012, 30:531.
• [42]Rimawi MF, Aleixo SB, Alarcon Rozas A, et al.: A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). ASCO Meeting Abstracts 2012, 30:606.
• [43]Tsang RY, Finn RS: Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012, 106:6-13.
• [44]Harbeck N, Im S-A, Huang C-S, et al.: LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. ASCO Meeting Abstracts 2012., 30TPS649
• [45]Hickish T, Tseng L-M, Mehta AO, et al.: LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatinib (L). ASCO Meeting Abstracts 2012., 30TPS651
• [46]Joensuu H, Ould KM: LUX-breast 3: Randomized phase II study of afatinib alone or with vinorelbine versus investigator’s choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy. ASCO Meeting Abstracts 2012., 30TPS647
• [47]Swanton C: Cromer J,89 study group. Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC). ASCO. Meeting Abstracts 2012., 30TPS650
• [48]Rabindran SK, et al.: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004, 64:3958-65.
• [49]Burstein HJ, et al.: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28:1301-7.
• [50]ClinicalTrials.gov [Internet]: Bethesda (MD): National Library of Medicine (US). 2009 April 8. Identifier NCT00878709, Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET). 2009. http://clinicaltrials.gov/show/NCT00878709 webcite
• [51]Canonici A, Pedersen K, Walsh N, Crown J, O’Donovan N: Effect of neratinib (N) alone and in combination with trastuzumab (T) in HER2-positive breast cancer (BC) cell lines. ASCO Meeting Abstracts 2012, 30:632.
• [52]Jankowitz RC, Abraham J, Tan AR, et al.: A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSABP FB-8. ASCO Meeting Abstracts 2012, 30:611.
• [53]Freedman RA, Gelman RS, Wefel JS, et al.: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases. 2012, 561s-562s. [San Antonio Breast Conference Abstracts]
• [54]Higgins MJ, Baselga J: Targeted therapies for breast cancer. J Clin Investig 2011, 121:3797-3803.
• [55]Bose R, Kavuri SM, Searleman AC, et al.: Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013, 3(2):224-37.
• [56]Hu C, Huang L, Xi X, et al.: Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. J Hematol Oncol 2012, 5:16. BioMed Central Full Text